SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes ...
What if instead of temporarily relieving your allergies with medication, you could train your immune system to stop overreacting to your allergens altogether? That’s the idea behind allergy ...
Participants in the OUtMATCH trial are allergic to peanuts and at least two other foods among milk, eggs, wheat, cashews, walnuts and hazelnuts. A clinical trial has found that the medication ...
Please provide your email address to receive an email when new articles are posted on . Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% ...
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...
Recent developments in allergen immunotherapy, improvements in primary care, and the emergence of a new treatment for other allergic conditions have improved the quality of care for seasonal allergies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results